logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

Travere Therapeutics: Treating IgA Nephropathy and Focal Segmental Glomerulosclerosis

IgA Nephropathy  Searching for companies focused on treating severe diseases that have yet to find approved drugs is one of Prohost Biotech 's tasks.  Recently we wrote about firms that have, in their pipelines, products that aim at treating NASH...

Read More

October 14, 2022

0

AstraZeneca: Tagrisso Recommended for Marketing Authorization in the EU for Early Stage EGFRm NSCLC

AstraZeneca: Tagrisso for Adult Patients with Early-Stage EGFRm NSCLC... AstraZeneca ( AZN ): Tagrisso (osimertinib) has been recommended for marketing authorization in the European Union for the adjuvant treatment of adult patients with early-stage ( IB, II and IIIA )...

Read More

April 27, 2021

0

Gilead Sciences Conference Call Information. See Also: Compugen Announcements

Gilead Sciences First-Quarter 2021 Financial Results Conference Call Info Gilead Sciences ( GILD ) management will host a conference call to discuss the company’s first-quarter 2021 financial results and will provide a business update today, Thursday, April 29, at 4:30...

Read More

April 29, 2021

0

At 2:30 PM Today the Chairman of the Federal Reserve will Reveal the Decision About Interest Rates. See Also: Good News from Gilead

Today at 2.30... Today at 2.30, the Federal Reserve Chairman Jerome Powell will speak to the United States and the rest of the world about the Fed’s decision with regard to interest rates. Financial analysts in five star financial journals...

Read More

June 14, 2023

0

Acumen Pharmaceuticals: New Effort to Treat Alzheimer’s Disease Granted FDA Fast Track Designation

Acumen Pharmaceuticals Product ACU193 On October 23, 2022, Acumen Pharmaceuticals ( ABOS ) announced that the first clinical-stage monoclonal antibody ACU193 - an anti-amyloid beta oligomer antibody, which selectively targets toxic soluble amyloid beta oligomers ( AβOs ), has been granted...

Read More

October 25, 2022

0

Vera Therapeutics Announces Positive Week 36 Safety and Efficacy Results in Phase 2b Clinical Trial of Atacicept in IgA Nephropathy

Vera Therapeutics Vera Therapeutics ( VERA ) announced that Phase 2b ORIGIN clinical trial of atacicept for IgA nephropathy  met its primary and key secondary endpoints, with statistically significant and clinically meaningful reductions in proteinuria and stabilization of eGFR through...

Read More

June 20, 2023

0

Reata Pharmaceuticals Announces 3Q 2022 Financial Results and an Update on Clinical Development Programs

Reata Pharmaceuticals Announcements The FDA decision not to hold an Advisory Committee Meeting to discuss Reata Pharmaceuticals product Omaveloxolone for the treatment of Friedreich’s ataxia hints to good news about the approval of this product approval on  February 2023.   The...

Read More

November 9, 2022

0

A Note To Our Followers

Dear Friends and Followers, We confirm our optimism towards the future biotech firms that we selected for investment, including the clinical stage small biotech companies, which also includes biotech stocks that you have never heard about from us.  We  inform...

Read More

December 23, 2022

0

Sutro Biopharma: First Quarter Financial Results, Business Highlights and More

Sutro Biopharma Inc Sutro Biopharma ( STRO ) is a clinical-stage drug discovery, development and manufacturing company. Its expertise is in the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics. Sutro Biopharma reported its...

Read More

May 10, 2021

0

Cassava Sciences Awarded NIH Grant. See Also: Intellia Therapeutics Presentations at the 24th ASGCT Meeting

Cassava Sciences Awarded NIH Research Grant for Simufilam Cassava Sciences ( SAVA ) announced that it has been awarded a new $2.7 million research grant from the National Institutes of Health ( NIH ). The grant was awarded following a...

Read More

May 12, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 43
  • 44
  • 45
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy